Physician profile
Christopher Lew
NPI 1043771082
$1,059.31
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.20 · 2022: $642 · 2023: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $138.96 | 2022 | |
| Edwards Lifesciences Corporation | $130.94 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $118.26 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $118.06 | 2022 | |
| Abbvie INC. | $117.17 | 2023 | |
| Astellas Pharma US INC | $115.40 | 2022 | |
| Amgen INC. | $112.07 | 2023 | Repatha |
| Janssen Pharmaceuticals, INC | $51.35 | 2022-2023 | Xarelto |
| Boston Scientific Corporation | $43.51 | 2022 | |
| Novo Nordisk INC | $33.82 | 2021-2022 | |
| Inari Medical, INC. | $18.94 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.36 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.96 | 2022 | |
| Lilly USA, LLC | $14.94 | 2021 | |
| Merck Sharp & Dohme LLC | $14.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.